OTCMKTS:SZLSF StageZero Life Sciences (SZLSF) Stock Price, News & Analysis → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free SZLSF Stock Alerts $0.01 -0.01 (-37.02%) (As of 06/5/2024) Add Compare Share Share Today's Range$0.0131▼$0.013150-Day Range$0.01▼$0.0452-Week Range$0.01▼$0.06Volume1,000 shsAverage Volume9,594 shsMarket Capitalization$1.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsSEC FilingsShort Interest Get StageZero Life Sciences alerts: Email Address Ad Market Moving TrendsTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Click to View The 5 Best AI Stocks to Invest In About StageZero Life Sciences Stock (OTCMKTS:SZLSF)StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.Read More SZLSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SZLSF Stock News HeadlinesMay 17, 2024 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational UpdateApril 5, 2024 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences Provides an Update on Application for Management Cease Trade OrderNovember 15, 2023 | seekingalpha.comStagezero Life Sciences GAAP EPS of -$0.01, revenue of $0.75MJune 7, 2023 | finance.yahoo.comStageZero Life Sciences, Ltd Announces Results of Resolutions at Annual and Special MeetingMay 17, 2023 | theglobeandmail.comDually-Listed Healthcare Stock Rallies On Q1 ResultsMay 15, 2023 | finance.yahoo.comStageZero to Issue Q1 2023 Financial Results After Market Closes May 15, 2023April 4, 2023 | msn.comStagezero Life Sciences GAAP EPS of -$0.09, revenue of $0.7MMarch 30, 2023 | finance.yahoo.comStageZero to Issue Q4 2022 Financial Results on Friday March 31March 29, 2023 | finance.yahoo.comStageZero to Issue Q4 2022 Financial Results and Hold Conference Call on Thursday March 30February 15, 2023 | finance.yahoo.comResults from METRICs Study Informs Expansion of StageZero's New Care Oncology ProtocolJanuary 12, 2023 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences Announces Extension of Warrants Expiring in January 2023January 12, 2023 | finance.yahoo.comStageZero Life Sciences Announces Extension of Warrants Expiring in January 2023November 15, 2022 | seekingalpha.comStageZero Life Sciences Ltd. (SZLSF) Q3 2022 Earnings Call TranscriptNovember 12, 2022 | finance.yahoo.comStageZero to Hold Q3 2022 Operational and Financial Results Conference Call on Tuesday November 15, 2022August 19, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Announces Solutions for Employers to Help Improve Cancer OutcomesAugust 12, 2022 | finance.yahoo.comStageZero to Hold Q2 2022 Operational and Financial Results Conference Call on Tuesday August 16, 2022May 26, 2022 | seekingalpha.comStageZero Life Sciences CFO resignsMay 25, 2022 | finance.yahoo.comStageZero Life Sciences Partners with DiagnoseAtHome to Offer Aristotle(R) Multi-Cancer Blood Test in Canada and USAMay 17, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences, Ltd Announces Q1 2022 Financial Results and Operational UpdateMay 17, 2022 | finance.yahoo.comStageZero Life Sciences, Ltd Announces Q1 2022 Financial Results and Operational UpdateApril 6, 2022 | finance.yahoo.comStageZero Life Sciences, Ltd Announces Corporate UpdateApril 1, 2022 | finance.yahoo.comStageZero Life Sciences, Ltd Announces Q4 2021 and Year End Financial Results and Operational UpdateMarch 31, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences Launches AVRT in the UKMarch 31, 2022 | finance.yahoo.comStageZero Life Sciences Launches AVRT(TM) in the UKMarch 14, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: CORRECTING AND REPLACING: StageZero Life Sciences Announces Availability of COC Protocol in EuropeSee More Headlines Receive SZLSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolOTCMKTS:SZLSF CUSIPN/A CIK1454263 Webwww.stagezerolifesciences.com Phone(855) 420-7140Fax905-209-2031Employees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,410,000.00 Net Margins-418.64% Pretax Margin-418.63% Return on EquityN/A Return on Assets-1,872.84% Debt Debt-to-Equity RatioN/A Current Ratio0.04 Quick Ratio0.03 Sales & Book Value Annual Sales$3.80 million Price / Sales0.43 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-0.19Miscellaneous Outstanding Shares123,530,000Free Float120,395,000Market Cap$1.62 million OptionableNot Optionable Beta0.43 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. James R. Howard-TrippExecutive Chairman & CEODr. Choong-Chin Liew Ph.D.Co-FounderMr. Warren Whitehead C.M.A. (Age 72)CPA, Chief Accountant Key CompetitorsBiomericaNASDAQ:BMRAMyMD PharmaceuticalsNASDAQ:MYMDStageZero Life SciencesOTCMKTS:GNWSFVirax Biolabs GroupNASDAQ:VRAXGlobal WholeHealth PartnersOTCMKTS:GWHPView All Competitors SZLSF Stock Analysis - Frequently Asked Questions How have SZLSF shares performed in 2024? StageZero Life Sciences' stock was trading at $0.0294 at the beginning of 2024. Since then, SZLSF stock has decreased by 55.4% and is now trading at $0.0131. View the best growth stocks for 2024 here. Are investors shorting StageZero Life Sciences? StageZero Life Sciences saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 16,300 shares, a decline of 31.8% from the April 30th total of 23,900 shares. Based on an average trading volume of 1,800 shares, the short-interest ratio is presently 9.1 days. View StageZero Life Sciences' Short Interest. How do I buy shares of StageZero Life Sciences? Shares of SZLSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SZLSF) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding StageZero Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share StageZero Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.